Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

NCT03358017 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Zoledronate
DRUG: Atorvastatin 80mg
DRUG: Standard neoadjuvant cht

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]